In a landmark study by Ahmed et al. (2015), potent anti-tumour activity of HER2-specific CAR-T cells against autologous HER2-positive glioblastoma multiforme (GBM) was shown, including regression of intracranial GBM xenografts in murine models [27]. This evidence concerns the gene ERBB2 and glioblastoma.